Lundbeck Completes Patient Enrollment in Phase III Dravet Syndrome Trial
Event summary
- Lundbeck has completed patient randomization in DEEp SEA (NCT06660394), a Phase III trial evaluating bexicaserin for Dravet syndrome.
- The trial enrolled over 100 participants aged 2 to 65 years, with the option to transition into a 52-week open-label extension.
- DEEp SEA is one of two pivotal trials in Lundbeck's global Phase III DEEp program, with DEEp OCEAN (NCT06719141) having completed randomization in July 2026.
- Bexicaserin has received Breakthrough Therapy designation from both the FDA and Chinese regulators for treating seizures associated with DEEs.
The big picture
Lundbeck's completion of patient enrollment in the DEEp SEA trial marks a critical step in its efforts to address the unmet needs in treating Dravet syndrome, a rare and severe form of epilepsy. The Phase III program's progress reflects the company's strategic focus on neurodevelopmental disorders, leveraging its expertise in neuroscience to develop transformative therapies. The Breakthrough Therapy designations from both the FDA and Chinese regulators underscore the potential of bexicaserin to fill a significant gap in the treatment landscape for developmental and epileptic encephalopathies.
What we're watching
- Regulatory Momentum
- Whether the Breakthrough Therapy designations will accelerate bexicaserin's approval process in key markets.
- Clinical Efficacy
- The reduction in countable motor seizure frequency as a key efficacy endpoint in the Phase III trials.
- Market Differentiation
- How bexicaserin's dual mode of action positions it against existing treatments for DEEs.